Test environment running 7.6.6

Cultural advice

The Australian National University acknowledges, celebrates and pays our respects to the Ngunnawal and Ngambri people of the Canberra region and to all First Nations Australians on whose traditional lands we meet and work, and whose cultures are among the oldest continuing cultures in human history.

Aboriginal and Torres Strait Islander peoples are advised that ANU Library collections may include images, names, voices, and other representations of deceased persons.

Material in the collection may contain terms, language or views that reflect the period in which the item was created and may be considered inappropriate today.

The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy

Thumbnail Image

Date

2009

Authors

Ellis, Leigh
Bots, Michael
Lindemann, Ralph K.
Bolden, Jessica E.
Newbold, Andrea
Cluse, Leonie A.
Scott, Clare L.
Strasser, Andreas
Atadja, Peter
Lowe, Scott W.

Journal Title

Journal ISSN

Volume Title

Publisher

American Society of Hematology

Abstract

LAQ824 and LBH589 (panobinostat) are histone deacetylase inhibitors (HDACi) developed as cancer therapeutics and we have used the Eμ-myc lymphoma model to identify the molecular events required for their antitumor effects. Induction of tumor cell death w

Description

Keywords

Citation

URI

http://hdl.handle.net/1885/34037

Collections

Open Access Research

Source

Blood

Type

Journal article

Book Title

Entity type

Access Statement

License Rights

DOI

10.1182/blood-2008-10-182758

Restricted until

2037-12-31

Downloads

File
Description
01_Ellis_The_histone_deacetylase_2009.pdf (2.92 MB)

DSpace software copyright © 2002-2026 LYRASIS